@article{article_1745105, title={Surfactant treatment in newborns other than respiratory distress syndrome}, journal={Pamukkale Medical Journal}, volume={19}, pages={1–1}, year={2025}, DOI={10.31362/patd.1745105}, author={Özdemir, Özmert M.a.}, keywords={Yenidoğan, sürfaktan, tedavi}, abstract={Surfactant, a phospholipid mixture, reduces surface tension and keeps the alveoli open. In its deficiency, widespread atelectasis develops and, as a result, ventilation perfusion balance and gas exchange are impaired. Surfactant is produced in lung type II alveolar cells and is mainly used intratracheally in the treatment of respiratory distress syndrome (RDS), a disease of premature babies. However, recently, the use of exogenous surfactant and its potential benefits have also begun to be emphasized in some diseases such as infection (pneumonia), aspiration (meconium) and congenital pulmonary malformation (diaphragmatic hernia) that develop due to secondary surfactant insufficiency, especially in late premature and term babies. In this review, the use of surfactant in non-RDS diseases that cause secondary surfactant deficiency in the lungs in newborn babies, its effectiveness and side effects are discussed with current literature data and guidelines, and scientific recommendations are presented.}, number={1}, publisher={Pamukkale Üniversitesi}, organization={yok}